A defensible recommendation
A clear recommendation, with the options and trade-offs where the decision warrants them, the assumptions behind it, the evidence supporting it and the factors that could change it.
VISFO Projects
Important answers. Delivered while they still matter.
Bespoke strategic projects for medical affairs, market access and launch teams. We combine life sciences expertise, data science, AI and product thinking to turn complex evidence into a clear, defensible recommendation, often in weeks rather than quarters.
Medical affairsMarket accessEvidence strategyLaunch planning
VISFO ProjectsTypical projects
What you actually receive.
- Strategic recommendation
- Evidence review
- Interactive decision model
- Executive presentation
- Supporting data pack
Delivered as a decision you can defend.
Some questions cannot wait six months.
Most teams are not short of information.
They have literature, consultancy reports, KOL interviews, payer research, congress notes and internal opinions. What they lack is a reliable way to bring it together quickly enough to support the decision in front of them.
We frame the question, assemble the evidence, expose where it disagrees and turn it into a recommendation your team can act on and defend.
What changes
What changes when you work with us.
- 01
From scattered evidenceOne shared picture
Relevant literature, HTA decisions, congress activity, stakeholder perspectives, patient evidence and internal materials brought together around the decision.
- 02
From competing opinionsVisible trade-offs
We don't hide disagreement. We show where evidence, reviewers and stakeholders diverge, then make the reasoning behind the final recommendation explicit.
- 03
From a static reportA working recommendation
Where useful, formal deliverables can be supported by interactive maps, models, scenarios or evidence views built around the question.
- 04
From a long projectA timely decision
You see an initial direction while there is still time to challenge it. The work sharpens through review rather than disappearing for months before a final presentation.
Deliverables
What you receive.
Everything needed to make and defend the decision.
The evidence
A structured evidence base your team can review, challenge and return to. Evidence-based claims remain connected to their sources, with assumptions and expert judgements made explicit.
The documents
The formal outputs required for internal review, governance and implementation.
These may include
- Executive presentations
- Strategic recommendations
- Dossiers and briefing books
- Target product profiles
- Evidence matrices
- Models and supporting data packs
An interactive view, where useful
Where it helps the decision, formal deliverables can be supported by a purpose-built way to interrogate the work rather than simply read it. Some projects are agreed as documents alone.
Depending on the question and agreed scope
- A filterable KOL map
- A scoreable HTA landscape
- A scenario model
- A TPP trade-off explorer
- An evidence-gap view
- A congress intelligence explorer
Delivered together through a secure project space shaped around your question. Your evolving outputs are accessible through the project from day one.
How we work
One question. Four moves.
- 01 / 04
Frame
We turn the decision into a precise question and agree what evidence would constitute a defensible recommendation. The output is not a scope document. It is a shared definition of the decision, the proof required and the people who need to sign behind it.
- 02 / 04
Build the evidence
We bring together the sources that matter, from published literature and HTA precedent to congress activity, stakeholder discourse, patient perspectives and internal evidence. Evidence-based claims remain connected to their sources, with assumptions and expert judgements made explicit.
- 03 / 04
Resolve the decision
We analyse, score, compare and synthesise. Contradictions are surfaced rather than smoothed over, assumptions are named, trade-offs and options become visible, and the recommendation strengthens through structured review.
- 04 / 04
Deliver it to be used
The finished documents are delivered with any agreed interactive views. Your team can present the recommendation, inspect the supporting evidence and test the assumptions without rebuilding the work in another spreadsheet.
“Most teams don't need more information. They need a clear answer, faster, and the conviction to act on it.”
Timeline
See the emerging recommendation before the final presentation.
Traditional project work often disappears into research before returning as a finished deck. We work differently.
An illustrative timeline for a typical defined project. Actual timing depends on scope, data access, evidence requirements and review cycles. Larger workstreams such as global value dossiers, systematic reviews, economic modelling and HTA submissions run considerably longer.
Days 1–5
The question and evidence standard are agreed
The decision, the evidence standard, the assumptions and the reviewers are agreed together.
Week 2
An initial direction is shared early
An early synthesis, as soon as the evidence allows. Timing depends on data acquisition, interviews and the scale of the evidence review.
Weeks 4–6
The reasoning becomes defensible
Evidence gaps, disagreement and trade-offs worked through with named reviewers and visible sources.
Weeks 6–10
Finished and ready to use
The final documents are delivered, with any agreed interactive views.
- Days 1–5
The question and evidence standard are agreed
The decision, the evidence standard, the assumptions and the reviewers are agreed together.
- Week 2
An initial direction is shared early
An early synthesis, as soon as the evidence allows. Timing depends on data acquisition, interviews and the scale of the evidence review.
- Weeks 4–6
The reasoning becomes defensible
Evidence gaps, disagreement and trade-offs worked through with named reviewers and visible sources.
- Weeks 6–10
Finished and ready to use
The final documents are delivered, with any agreed interactive views.
Engagement models
Three ways to engage.
Pick the one that fits your question. If it's the wrong fit, we'll say so.
Compare
One defined decision
Focused answer
Linked questions and workstreams
Project
Keep the picture current
Standing intelligence
Best for
One defined decision, a compact evidence base and a rapid recommendation
Several linked questions, workstreams or stakeholders, with formal deliverables
Ongoing monitoring, interpretation and scheduled strategic updates as evidence, policy or competitor positions change
Indicative duration
2–3 weeks
Often 6–10 weeks, longer where scope, data access or review requirements demand it
Rolling 90-day periods
You receive
A recommendation, the evidence synthesis behind it and a decision view
The agreed deliverables and evidence base, with interactive views where useful
Refreshed evidence, updated recommendations and maintained project views
Team
A lead with a relevant domain reviewer
A project team configured around the question, typically including a lead, analysts and relevant domain reviewers, with data science, design and engineering support where required
A small VISFO team working with yours each week
Durations are indicative. Timing depends on scope, data access and review requirements.
How we operate
How we work.
Four things you can expect from us on every project.
- 01
Fast, but you can still see the working.
Moving quickly should not mean cutting corners. Evidence-based conclusions remain connected to their sources, with assumptions, expert judgements and the reviewers who stood behind them made explicit.
- 02
Documents, and decision tools where they help.
You get the documents your organisation needs for review and sign-off. Where useful, those can be supported by interactive views that let people check the thinking behind them.
- 03
Disagreement made visible.
Confidence does not come from pretending every source agrees. It comes from understanding where disagreement exists and why the recommendation still holds.
- 04
Built to be used, not filed.
The goal is not the largest possible report. It is helping your team make the right call while there is still time to act on it.
Common questions
Questions we get asked.
01How fast can you actually move?
For a compact, well-defined question you will usually see an initial direction in the second week, and a finished document, whether that is a TPP, a landscape, a synthesis or a congress readout, inside a few weeks. Larger workstreams such as systematic reviews, economic models, global value dossiers and HTA submissions take longer, and timing depends on scope, data access and review requirements. The speed comes from the tools we use to gather, score and combine evidence. You get the recommendation, not the tools.
02Are you building us software?
No. Projects are bespoke analytical work, delivered through a secure project space so your team can work with the recommendation rather than only read it. Where an interactive view helps the decision, we build one into the scope. If you want software your team logs into long term, that is a separate conversation on the product side.
03Who owns the work, and what happens at the end?
Your evolving outputs are accessible through the project from day one, in standard formats you can export. Ownership of the agreed deliverables sits with you; the underlying platform, licensed source data and our own methods and IP remain ours. The project space stays available for an agreed period after handover, or stays live if you want us to keep the picture up to date.
04Where does this sit alongside our medical-affairs or market-access agency?
Alongside them, not in competition. The agency runs the programme, and we provide the evidence and analysis they brief from. Many clients use us to look after the synthesis, comparator sets and scoring once an agency engagement ends.
Where we work
The areas where we work.
01
Prioritise
Decide where to invest, what to pursue and what should happen next.
- Asset evaluation
- Opportunity sizing
- Target product profiles
- Trial design and development strategy
- Lifecycle and indication strategy
- BD and licensing diligence
- Launch readiness
02
Understand the landscape
Build a reliable view of the people, evidence, competitors and systems shaping the market.
- Therapy-area landscapes
- KOL mapping
- Competitive intelligence
- HTA landscape and precedent analysis
- Congress intelligence and strategy
03
Build the case for value
Create the evidence and arguments needed to support access and adoption.
- Clinical and access evidence strategy
- Regulatory and HTA evidence readiness
- Global value dossiers
- HTA and JCA readiness
- Evidence-gap analysis
- Pricing and reimbursement
- Health-economic modelling
- Real-world evidence strategy
04
Shape the strategy
Turn evidence into a plan that functions can align around and execute.
- Medical strategy
- Scientific narratives
- Integrated evidence planning
- Publication planning
- Patient strategy
- Positioning and messaging
Add the pieces you'd want to your scope and send it over. We'll come back with what we'd actually recommend, including anything you don't need.
Strategy
Scientific narrative
A defensible scientific spine every asset can pull from.
We produce the scientific platform, claim hierarchy, proof points and the connective tissue between them. Written up as a narrative document and a working session with medical, commercial and access.
Explore
Landscape
KOL mapping
A baseline map of the experts who shape your therapy area, with a plan to earn their time.
We identify, score and prioritise the experts that matter in your therapy area. You get a stakeholder map, scoring rubric and engagement plan the medical team can run from day one.
Visit
Read
Book
Meet
Strategy
Medical strategy
An independent read of your medical plan, every 12 months.
A structured read of the current medical plan, the gaps, the redundancies and where to concentrate spend over the next 12 months. Written up as a diagnostic with a steering-committee read-out.
Strategy
Publication planning
A 24-month publication plan anchored to the evidence gaps that matter.
We map the publication landscape, identify white space against the scientific narrative and produce a 24-month plan with target journals, congresses and authorship. Written up as a planning document with a working tracker.
Strategy
MSL insight analysis
Your MSL notes, scored, structured and turned into a decision.
A data science project on your real note corpus. Every insight scored against a rubric for insight quality and documentation quality, tagged, clustered and compliance-flagged, then handed back as findings, a scored dataset and coaching recommendations.
Explore
Strategy
MSL field enablement
The scientific story the field can actually carry into the room.
We turn the scientific narrative into field-ready materials: slide deck, objection handlers, reactive Q&A and a training session for the MSL team.
FUNDSeries A · €18m
HIREVP Clinical, NASH
TRIALPh2 readout · Q3
Strategy
Field medical excellence
Strategy-driven listening imperatives and note scoring, stood up in weeks.
We translate the medical strategy into listening imperatives per HCP, build the Insight Score rubric with your team and run the first coaching cycle on live MSL notes, before the platform layer takes over.
Explore
Strategy
Medical strategy operating model
Turn the strategy deck into the weighting the field actually works to.
We translate medical strategy into a small set of weighted objectives, the behaviours that move them and the measures that prove it, so priorities show up in day-to-day field decisions rather than an annual slide.
Visit
Read
Book
Meet
Landscape
HCP universe profiling
The whole treating universe, evidenced, not just the KOL shortlist.
We build a structured profile of every relevant HCP in scope, not only the published few, drawing on practice setting, referral position, trial and guideline activity, digital footprint and prior engagement.
Strategy
HCP need mapping
What each clinician actually needs, read at the individual level.
We map the scientific gaps, questions and barriers at individual HCP level and tie each to the medical objective it serves, so engagement answers a real need instead of delivering the same deck to everyone.
Strategy
Next best action design
Recommendation logic your medical team can explain and defend.
We design the rules that decide what happens next with a given HCP, need, objective weighting, recency and channel, and pressure-test them against real history before anything is automated.
Explore
Strategy
Engagement sequencing and territory plan
Who to see, in what order, and which trip it belongs to.
We turn priorities into a workable plan across geography and time, sequencing engagement around referral networks, congress dates and travel reality rather than a flat priority list.
FUNDSeries A · €18m
HIREVP Clinical, NASH
TRIALPh2 readout · Q3
Strategy
Field signal loop
MSL notes that come back as usable evidence, not free text in a box.
We structure what the field captures, how it is scored and where it lands, so interactions feed the stakeholder record and the strategy instead of disappearing into CRM. Over time that record shows what has actually shifted, which is what leadership gets shown instead of a count of meetings held.
Explore
Proof
Global value dossier
GVD development support, from module architecture to a first release, to the agreed scope.
We support global value dossier development as a set of reusable modules: claims, evidence, payer arguments. Depending on the agreed scope, that runs from the module architecture and evidence base through to drafting a v1 release your affiliate teams can localise market by market.
Visit
Read
Book
Meet
Proof
Payer value story
A sharp value story, pressure-tested against payer priorities and decision archetypes.
Workshop-led work that sharpens the value proposition, pressure-tests it against relevant payer priorities and decision archetypes, and produces a written objection-handling pack the access team can carry into the room. Testing with real payers can be added where primary research is in scope.
Proof
HTA submissions
Submission support tuned to each agency's expectations and the agreed scope.
Strategic, evidence and authoring support for submissions to NICE, HAS, G-BA and other agencies, tailored to the agreed scope and local requirements. Narrative, evidence strategy and review cycles tuned to each agency, delivered as draft sections and review-cycle working sessions.
Proof
Evidence gap map
What you have vs what payers and HTA are likely to ask, with a literature review underneath.
We run a targeted literature review, or support a systematic review to the agreed protocol and scope, map what you have against what payers and HTA agencies are likely to ask, score the gaps and hand over a ranked study shortlist with sizing, feasibility and a recommended sequence.
Explore
Proof
Pricing & reimbursement
Pricing corridors and a launch sequence the access team can defend.
We benchmark comparators, model pricing corridors and recommend a launch sequence by market, using available and appropriately comparable pricing and reimbursement evidence. Delivered as a pricing strategy document with the supporting model and, where useful, a live corridor view the team can interrogate.
FUNDSeries A · €18m
HIREVP Clinical, NASH
TRIALPh2 readout · Q3
Strategy
Advisory boards
Payer, scientific or patient. Recruited, run and synthesised against your real questions.
We recruit, run and synthesise a configurable advisory board (payer, scientific or patient) designed around the questions that matter. Written up as a structured read-out with implications by audience and market.
Explore
Proof
Country archetypes
A launch wave plan grounded in access readiness, not gut feel.
We segment target markets, score access readiness across HTA, pricing and reference effects, and produce a launch wave plan with rationale by country and a steering-committee read-out.
Visit
Read
Book
Meet
Proof
Integrated evidence plan
The anchor plan that aligns medical, access and HEOR evidence generation.
The cross-functional evidence plan that aligns medical, market access and HEOR around the questions each stakeholder will actually ask. Written up as an IEP with study shortlist, sequencing and named owners, plus a live portal the team runs against.
Proof
EU JCA & PICO
PICO-ready evidence and submission scaffolding for the EU Joint Clinical Assessment.
We pressure-test PICOs across member states, map evidence readiness against JCA requirements and hand over the scaffolding your team needs to submit: gap list, owners and timeline in a single readiness report.
Proof
Managed entry agreements
Strategic design support for outcomes-based, risk-share and managed-entry approaches.
We help shape the managed-entry approach (outcomes-based, risk-share or installment), sized to the asset, the payers and the data you can credibly produce. Written up as a strategic playbook with per-country options and a contracting decision tree. Negotiation and legal contracting stay with your teams.
Explore
Proof
Regulatory & HTA evidence readiness
Know what your evidence will withstand before the agencies test it.
A readiness assessment of the evidence base against regulatory and HTA expectations across priority markets, with the gaps, risks and remediation options set out before submission timelines close them off.
FUNDSeries A · €18m
HIREVP Clinical, NASH
TRIALPh2 readout · Q3
Proof
HTA landscape & precedent analysis
What agencies have accepted, challenged and rejected in your space.
A structured analysis of HTA decisions, critiques and precedent across the markets that matter, so the value case is built against how agencies have actually behaved rather than how guidance says they should.
Explore
Prioritise
Launch readiness
Where you really are, 12 to 24 months out.
A structured read of where the launch actually is 12 to 24 months out: capability gaps, decision debt, critical path. Written up as a diagnostic with a steering-committee read-out.
Visit
Read
Book
Meet
Strategy
Positioning & messaging
Positioning the whole organisation will actually sign behind.
Facilitated sessions that turn the raw asset story into positioning the whole organisation can sign behind. Written up as a positioning document, message map and workshop outputs.
Landscape
Competitive intelligence
A baseline CI read plus the watchlist worth running for the next 12 months.
We build your CI baseline across competitors, regulators and conferences, and hand over a prioritised watchlist with cadence and owners. Published as a live signal feed with quarterly cross-functional read-outs.
Strategy
Brand planning
A v1 brand plan the cross-functional team will actually sign.
We build the v1 brand plan: strategic imperatives, tactics, KPIs. Written up as a brand plan document ready for cross-functional sign-off.
Explore
Prioritise
Forecasting & opportunity sizing
An independent pressure test of the demand story.
An outside read of demand assumptions, comparator analogues and scenario ranges that pressure-tests the commercial case. Delivered as a written review with the working model and a scenario portal the leadership team can interrogate.
FUNDSeries A · €18m
HIREVP Clinical, NASH
TRIALPh2 readout · Q3
Prioritise
Lifecycle & indication strategy
A prioritised lifecycle roadmap, not a wish list.
We map follow-on indications, LOE risk and lifecycle plays into a prioritised roadmap. Written up as a sequencing plan with rationale and decision gates the cross-functional team will actually sign behind.
Explore
Prioritise
Asset evaluation
A structured read on whether the asset or indication is worth the next dollar.
A scoped diagnostic that pressure-tests an asset or indication against scientific, commercial and access criteria. Written up as an evaluation with a go / no-go recommendation, the assumptions it rests on and the watch-items that would change the call.
Visit
Read
Book
Meet
Prioritise
Target product profile
The minimum, target and aspirational profile the cross-functional team will sign behind.
We build the TPP across clinical, operational, access and commercial domains. Delivered as a versioned document and a live TPP grid with named attribute owners, evidence anchors and a trade-off register the team can revisit.
Prioritise
BD&L diligence
An independent diligence read on a candidate asset, ready for IC.
Independent commercial, scientific and access diligence on a target asset: comparator landscape, evidence read, value-story sense-check and access risks. Written up as an IC-ready memo with a working appendix and a clear recommendation.
Prioritise
Market sizing & epidemiology
A defensible epi-anchored sizing model the team can take to the board.
We build the epidemiology base (incidence, prevalence, treated population, line-of-therapy splits) and turn it into a sizing model with sources and assumptions named. Written up as a report with a live sizing portal the team can run against.
Explore
Landscape
Therapy area landscape
A defensible read of the therapy area: patients, pathways, competitors, evidence and policy, in one place.
A structured TA landscape covering disease, patient flow, current standards, competitor pipeline, evidence base and policy context. Written up as a report and a working session that grounds the cross-functional team in one shared picture of the playing field.
FUNDSeries A · €18m
HIREVP Clinical, NASH
TRIALPh2 readout · Q3
Landscape
Congress strategy
What to present, who to engage, where to invest, across the congress year.
We build the annual congress plan: priority meetings, presence model, scientific contributions, KOL engagement and measurement. Written up as a plan, a cross-functional read-out deck and a working tracker the medical team runs against the year.
Explore
Landscape
Conference planning
Turn one meeting into a planned operation, with a route through it for every person you send.
We plan a single conference properly: objectives taken from the strategic imperatives, the people who matter at this meeting, and a personal golden path for every field team member, which sessions, which stands, which conversations, in what order. Delivered as the plan, a per-person route pack and the measurement frame you judge it against afterwards.
Visit
Read
Book
Meet
Landscape
Conference listening
Hear the entire conversation around a meeting, not just the parts your team walked into.
We read the whole conversation around a moment in the calendar: social, digital, the session content itself, press and competitor activity, structured into themes, sentiment and share of voice. Run before to sharpen the plan, live to see what is landing, and after to give you the settled read.
Proof
Cost-effectiveness & budget impact
Adaptable global models with country-ready inputs, built for HTA scrutiny.
We build or support adaptable global cost-effectiveness and budget-impact models with country-ready inputs, transparent assumptions and a structure built to withstand HTA committee scrutiny. Delivered as a working model and technical report, with a live scenario view where it helps the team.
Proof
Real-world evidence strategy
An RWE roadmap tuned to the decisions it has to support.
We produce the RWE plan: data partnerships, study design, read-out cadence. Written up as a strategy and operating plan the HEOR team can run from.
Explore
Proof
Unmet need & burden
Publishable burden-of-illness work that anchors the unmet-need argument across access, advocacy and medical.
Publishable burden-of-illness and unmet-need work that quantifies the gap between current care and what patients actually need. Delivered as a study report and publication-ready manuscript, plus a live funnel portal that exposes per-step epi and cost overlay.
FUNDSeries A · €18m
HIREVP Clinical, NASH
TRIALPh2 readout · Q3
Proof
Indirect treatment comparison
A defensible ITC or NMA, prepared to support HTA submission.
Feasibility, network construction and the analysis itself, to the agreed method and scope. Delivered as an ITC or NMA technical report prepared to support HTA submissions.
Explore
Proof
Clinical & access evidence strategy
One evidence plan that serves the clinical programme and the access case.
We connect the clinical development plan to what payers and HTA agencies are likely to ask, so the evidence generated for regulators also supports the value case. Delivered as an evidence strategy with the gaps, the trade-offs and the sequencing made explicit.
Visit
Read
Book
Meet
Prioritise
Trial design & development strategy
Development choices tested against the questions the evidence will have to answer.
Strategic input into trial design and development choices: endpoints, comparators, populations and study sequencing, tested against regulatory, HTA and payer expectations. Advisory support alongside your clinical and regulatory teams, not a substitute for them.
Strategy
Patient journey
Journey maps grounded in primary research with patients and caregivers, not workshop hunches.
We build evidence-based journey maps from primary research with patients and caregivers: what they do, what they feel, where the caregiver burden actually sits, where you can credibly help. Delivered as journey artefacts and a working session with the cross-functional team.
Strategy
Patient advocacy
The long-view advocacy plan, the partner shortlist and the operating model for embedding patient voice.
We map patient advocacy organisations, set the strategy, hand over a partner shortlist with engagement priorities, and design the operating model for embedding patient voice across functions. Written up as a strategy document with governance and cadence.
Explore
Strategy
Patient preference & outcomes
What patients actually trade off, quantified, plus the PRO or COA scaffolding to carry it.
A quant and qual study capturing what patients trade off, paired with the PRO or COA selection or design that anchors it in label and value-story conversations. Delivered as a study report and read-out.
FUNDSeries A · €18m
HIREVP Clinical, NASH
TRIALPh2 readout · Q3
Build what comes next.
Whether you need growth, answers or capability, VISFO helps you move earlier and faster.